Is there a correlation between maternal serum TGF-β1 levels and fetal hydronephrosis?

References

• Zieg J, Blahova K, Seeman T, et al. Urinary transforming growth factor-β1 in children with obstructive uropathy. Nephrology (Carlton) 2011;16:595–8
   PubMed Web of Science ®Google Scholar
• Vasconcelos MA, Bouzada MC, Silveira KD, et al. Urinary levels of TGF β-1 and of cytokines in patients with prenatally detected nephrouropathies. Pediatr Nephrol 2011;26:739–47
   PubMed Web of Science ®Google Scholar
• de Grauw AM, den Dekker HT, de Mol AC, Rombout-de Weerd S. The diagnostic value of routine antenatal ultrasound in screening for congenital uropathies. J Matern Fetal Neonatal Med 2014;26:1–5
   Google Scholar
• Policiano C, Djokovic D, Carvalho R, et al. Ultrasound antenatal detection of urinary tract anomalies in the last decade: outcome and prognosis. J Matern Fetal Neonatal Med 2014 . [Epub ahead of print]. doi:10.3109/14767058.2014.939065
   PubMed Web of Science ®Google Scholar
• Chevalier RL. Pathogenesis of renal injury in obstructive uropathy. Curr Opin Pediatr 2006;18:153–60
   PubMed Web of Science ®Google Scholar
• Almodhen F, Loutochin O, Capolicchio JP, et al. The role of bladder urine transforming growth factorbeta1 concentrations in diagnosis and management of unilateral prenatal hydronephrosis. J Urol 2009;182:292–8
   PubMed Web of Science ®Google Scholar
• Gokce I, Alpay H, Biyikli N, et al. Urinary levels of interleukin-6 and interleukin-8 in patients with vesicoureteral reflux and renal parenchymal scar. Pediatr Nephrol 2010;25:905–12
   PubMed Web of Science ®Google Scholar
• Sevketoglu E, Yilmaz A, Gedikbasi A, et al. Urinary macrophage migration inhibitory factor in children with urinary tract infection. Pediatr Nephrol 2010;25:299–304
   PubMed Web of Science ®Google Scholar
• Taha MA, Shokeir AA, Osman HG, et al. Pelvi-ureteric junction obstruction in children: the role of urinary transforming growth factor-beta and epidermal growth factor. BJU Int 2007;99:899–903
   PubMed Web of Science ®Google Scholar
• Baskin LS, Kogan BA, Duckett JW. Handbook of pediatric urology. Philadelphia: Lippincott Williams & Willkins; 1997
   Google Scholar
• Bouzada MC, Oliveira EA, Pereira AK, et al. Diagnostic accuracy of fetal renal pelvis anteroposterior diameter as a predictor of uropathy: a prospective study. Ultrasound Obstet Gynecol 2004;24:745–9
   PubMed Web of Science ®Google Scholar
• Costa Santos C, Costa Pereira A, Bernardes J. Agreement studies in obstetrics and gynaecology: inappropriateness, controversies and consequences. BJOG 2005;112:667–9
   PubMed Web of Science ®Google Scholar
• Caubet C, Lacroix C, Decramer S, et al. Advances in urinary proteome analysis and biomarker discovery in pediatric renal disease. Pediatr Nephrol 2010;25:27–35
   PubMed Web of Science ®Google Scholar
• Furness PD, Maizels M, Han SW, et al. Elevated bladder urine concentration of transforming growth factor-beta1 correlates with upper urinary tract obstruction in children. J Urol 1999;162:1033–6
   PubMed Web of Science ®Google Scholar
• Mesrobian HG, Mitchell ME, See WA, et al. Candidate urinary biomarker discovery in ureteropelvic junction obstruction: a proteomic approach. J Urol 2010;184:709–14
   PubMed Web of Science ®Google Scholar
• Sharma K, Eltayeb BO, McGowan TA, et al. Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis 1999;34:818–23
   PubMed Web of Science ®Google Scholar
• Lemmens AS, Mekahli D, Devlieger R, et al. Population-specific serum creatinine centiles in neonates with posterior urethral valves already predict long-term renal outcome. J Matern Fetal Neonatal Med 2014 . [Epub ahead of print]. doi:10.3109/14767058.2014.942278
   PubMed Web of Science ®Google Scholar
• Klahr S. Urinary tract obstruction. Semin Nephro 2002;21:133–45
   Web of Science ®Google Scholar
• Chagraoui H, Giraudier S, Vainchenker W, Wendling F. Adenoviral supply of active transforming growth factor-beta1 (TGF-beta1) did not prevent lethality in transforming growth factor-beta1-knockout embryos. Eur Cytokine Network 2001;12:561–7
   PubMed Web of Science ®Google Scholar
• Letterio JJ, Gier AG, Kulkarni AB, et al. Maternal rescue of the transforming growth factor-beta1 null mice. Science 1994;264:1936
   PubMed Web of Science ®Google Scholar
• Sharma K, Jin Y, Guo J, et al. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996;45:522–30
   PubMed Web of Science ®Google Scholar
• Ziyadeh FN, Sharma K, Ericksen M, et al. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Invest 1994;93:536–42
   PubMed Web of Science ®Google Scholar
• Wong MG, Perkovic V, Woodward M, et al. Circulating bone morphogenetic protein-7 and transforming growth factor-β1 are better predictors of renal end points in patients with type 2 diabetes mellitus. Kidney Int 2013;83:278–84
   PubMed Web of Science ®Google Scholar
• August P, Suthanthiran M. Transforming growth factor beta and progression of renal disease. Kidney Int Suppl 2003;87:99–104
   Google Scholar
• Zitouni K, Harry DD, Nourooz-Zadeh J, et al. Circulating vitamin E, transforming growth factor beta1, and the association with renal disease susceptibility in two racial groups with type 2 diabetes. Kidney Int 2005;67:1993–1998
   PubMed Web of Science ®Google Scholar
• Kumar A, Gupta V, Chaudhary M, et al. Depleted TGF-β1 levels in end stage renal disease patients from North India. Gene 2014;534:440–3
   PubMed Web of Science ®Google Scholar